INS and Other metabolic disease: For instance, in cancer chemoprevention research, EGCG treatment has been demonstrated to induce promoter demethylation and restore expression of various tumor suppressor genes (such as p16INK4a and RARβ); in metabolic disease models, its epigenetic regulatory role has also been shown to contribute to improving the expression of key genes in the insulin signaling pathway [59].